Skinfold measurements is one of the most popular and practical methods for estimating percent body fat. Body composition is a term that describes the relative proportions of fat, bone, and muscle mass in the human body. Following the collection of skinfold measurements, regression analysis (a statistical procedure used to predict a dependent variable based on one or more independent or predictor variables) is used to estimate total percent body fat in humans. <doi:10.4324/9780203868744>.

Real-time quantitative polymerase chain reaction (qPCR) data
    sets by Boggy et al. (2008) <doi:10.1371/journal.pone.0012355>. This package
    provides a dilution series for one PCR target: a random sequence that
    minimizes secondary structure and off-target primer binding. The data set
    is a six-point, ten-fold dilution series.
    For each concentration there are two replicates. Each amplification curve
    is 40 cycles long. Original raw data file:
    <https://journals.plos.org/plosone/article/file?type=supplementary&id=10.1371/journal.pone.0012355.s004>.

Generic Extraction of main text content from HTML files; removal
    of ads, sidebars and headers using the boilerpipe 
    <https://github.com/kohlschutter/boilerpipe> Java library. The
    extraction heuristics from boilerpipe show a robust performance for a wide
    range of web site templates.

The Bayesian optimal interval (BOIN) design is a novel phase I
    clinical trial design for finding the maximum tolerated dose (MTD). It can be
    used to design both single-agent and drug-combination trials. The BOIN design
    is motivated by the top priority and concern of clinicians when testing a new
    drug, which is to effectively treat patients and minimize the chance of exposing
    them to subtherapeutic or overly toxic doses. The prominent advantage of the
    BOIN design is that it achieves simplicity and superior performance at the same
    time. The BOIN design is algorithm-based and can be implemented in a simple
    way similar to the traditional 3+3 design. The BOIN design yields an average
    performance that is comparable to that of the continual reassessment method
    (CRM, one of the best model-based designs) in terms of selecting the MTD, but
    has a substantially lower risk of assigning patients to subtherapeutic or overly
    toxic doses. For tutorial, please check Yan et al. (2020) <doi:10.18637/jss.v094.i13>.